Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Developing an assay for proteolyzed and intact cardiac troponin I to distinguish patients having mild versus severe ischemic disease.

FY 2023-24

Summary
Introduction: Myocardial infarction (MI) is a leading cause of mortality in the developed world, accounting for one third of the deaths associated with ischemic heart disease. The damaged heart muscle releases proteins such as cardiac troponin into the blood. The cardiac troponin assay is the most sensitive method for detecting a MI. Troponin is susceptible to proteolysis by proteases such as matrix metalloproteinases, creating a heterogenous mixture of proteolyzed products. This complicates the standardization and measurement of current clinical assays. Our lab previously developed a prototype assay which distinguished between intact troponin and proteolyzed fragments using a combination of immunoassays that employ antibodies detecting different regions of cardiac troponin I (cTnI). Our study proposed that cardiac strain released more intact troponin, whereas true myocardial infarction leading to cell death released more proteolyzed fragments. The desired assay requires accurate quantification and specificity to establish a relationship between the ratio of intact to proteolyzed cTnI and the type of myocardial injury assessed in patients. This will improve the diagnostic function of clinical assays. Hypothesis: The cTnI released in myocardial infarct will be more fragmented that intact cTnI released by milder ischemic injury. Objectives: 1. Develop a high sensitivity assay using antibodies targeting specific epitopes of cTnI to quantify proteolyzed versus intact troponin. 2. Evaluate an engineered soluble form of cardiac troponin I as reference material for the assay developed in Objective 1. 3. Use the new assay to quantify proteolyzed and intact cTnI in blood plasma samples in patients presenting with diverse mechanisms and severities of myocardial injury.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
505984
Name
Dodia Kuldeepsinh
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing an assay for proteolyzed and intact cardiac troponin I to distinguish patients having mild versus severe ischemic disease.
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibodies; Biomarkers; Blood Samples; Cardiac Strain; Cardiac Troponin; Cardiovascular; Detection Assay; Matrix Metalloproteinases; Myocardial Infarction; Proteolysis
Abstract
Introduction: Myocardial infarction (MI) is a leading cause of mortality in the developed world, accounting for one third of the deaths associated with ischemic heart disease. The damaged heart muscle releases proteins such as cardiac troponin into the blood. The cardiac troponin assay is the most sensitive method for detecting a MI. Troponin is susceptible to proteolysis by proteases such as matrix metalloproteinases, creating a heterogenous mixture of proteolyzed products. This complicates the standardization and measurement of current clinical assays. Our lab previously developed a prototype assay which distinguished between intact troponin and proteolyzed fragments using a combination of immunoassays that employ antibodies detecting different regions of cardiac troponin I (cTnI). Our study proposed that cardiac strain released more intact troponin, whereas true myocardial infarction leading to cell death released more proteolyzed fragments. The desired assay requires accurate quantification and specificity to establish a relationship between the ratio of intact to proteolyzed cTnI and the type of myocardial injury assessed in patients. This will improve the diagnostic function of clinical assays. Hypothesis: The cTnI released in myocardial infarct will be more fragmented that intact cTnI released by milder ischemic injury. Objectives: 1. Develop a high sensitivity assay using antibodies targeting specific epitopes of cTnI to quantify proteolyzed versus intact troponin. 2. Evaluate an engineered soluble form of cardiac troponin I as reference material for the assay developed in Objective 1. 3. Use the new assay to quantify proteolyzed and intact cTnI in blood plasma samples in patients presenting with diverse mechanisms and severities of myocardial injury.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dodia, Kuldeepsinh
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~